Literature DB >> 8887952

Cardiac function, metabolism and perfusion in Duchenne and Becker muscular dystrophy.

R M Quinlivan1, P Lewis, P Marsden, R Dundas, S A Robb, E Baker, M Maisey.   

Abstract

We studied 23 DMD and eight BMD patients using cardiac echo, 24 h ECG and positron emission tomography (PET) with the radiotracers N-13 ammonia and F-18 fluorine deoxyglucose. The ECG was abnormal in 23 cases with alterations in the PR and/or QT intervals, abnormal Q waves in the lateral leads and ST segment depression. Twenty-four hour ECG showed that patients were more likely to produce premature ventricular ectopic beats with advancing age and 17 patients had paroxysmal ST segment depression. LV function was normal or mildly reduced in 24 cardiac echoes. PET studies were visibly abnormal in 15 patients. Regional perfusion defects involving the apex, lateral or anterior left ventricular walls were present, nine cases demonstrated a corresponding increase in glucose metabolism. Three out of 15 demonstrated matched perfusion/metabolism defects. One BMD had severe LV dilation with globally poor perfusion and metabolism. The abnormalities seen with PET were confirmed with both quantitative and semi-quantitative analysis of radioactive counts. Similar results were obtained for both DMD and BMD, where both groups demonstrated significant regional perfusion/metabolism mismatches. We have shown a reduced uptake of N-13 ammonia which is indicative of a reduction in myocardial perfusion. The use of N-13 ammonia to measure perfusion has been validated in animal studies. PET with either N-13 ammonia- or oxygen labelled water can be used to measure myocardial perfusion. We chose N-13 ammonia as this was most readily available to us.

Entities:  

Mesh:

Year:  1996        PMID: 8887952     DOI: 10.1016/0960-8966(96)00007-7

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  9 in total

Review 1.  Positron emission tomography in paediatric cardiology.

Authors:  R M Quinlivan; R O Robinson; M N Maisey
Journal:  Arch Dis Child       Date:  1998-12       Impact factor: 3.791

Review 2.  Cardiopulmonary support in duchenne muscular dystrophy.

Authors:  Josef Finsterer
Journal:  Lung       Date:  2006 Jul-Aug       Impact factor: 2.584

Review 3.  Alterations in mitochondrial function as a harbinger of cardiomyopathy: lessons from the dystrophic heart.

Authors:  Yan Burelle; Maya Khairallah; Alexis Ascah; Bruce G Allen; Christian F Deschepper; Basil J Petrof; Christine Des Rosiers
Journal:  J Mol Cell Cardiol       Date:  2009-09-18       Impact factor: 5.000

4.  Severe cardiomyopathy in mice lacking dystrophin and MyoD.

Authors:  L A Megeney; B Kablar; R L Perry; C Ying; L May; M A Rudnicki
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

Review 5.  Cardiac involvement in Becker muscular dystrophy.

Authors:  Josef Finsterer; Claudia Stöllberger
Journal:  Can J Cardiol       Date:  2008-10       Impact factor: 5.223

6.  Use of imaging biomarkers to assess perfusion and glucose metabolism in the skeletal muscle of dystrophic mice.

Authors:  Nabeel Ahmad; Ian Welch; Robert Grange; Jennifer Hadway; Savita Dhanvantari; David Hill; Ting-Yim Lee; Lisa M Hoffman
Journal:  BMC Musculoskelet Disord       Date:  2011-06-04       Impact factor: 2.362

7.  Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.

Authors:  John P Bourke; Teofila Bueser; Rosaline Quinlivan
Journal:  Cochrane Database Syst Rev       Date:  2018-10-16

8.  SPECT Imaging of Muscle Injury with [99mTc]MDP in a Mouse Model of Muscular Dystrophy.

Authors:  Carolynn Gaut; Jenna M Sullivan; Barbara Biscaro; Edward J Soares; Katharine Nicholson; Jack Hoppin; Ajay Verma
Journal:  Mol Imaging Biol       Date:  2020-06       Impact factor: 3.488

Review 9.  Cardiac MRI biomarkers for Duchenne muscular dystrophy.

Authors:  Patrick Magrath; Nyasha Maforo; Pierangelo Renella; Stanley F Nelson; Nancy Halnon; Daniel B Ennis
Journal:  Biomark Med       Date:  2018-11-30       Impact factor: 2.851

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.